Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)
Elizabeth Finger(Western University), Adam L. Boxer(University of California, San Francisco), Howard Feldman(University of British Columbia), Kristy Coleman(Lawson Health Research Institute), Jeffrey Cummings(Cleveland Clinic), Ging‐Yuek Robin Hsiung(University of British Columbia), Scott Berry(Queen's University)
Cited by 35
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
|Nature|2006|2.1k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k